Serotype Distribution among Streptococcus pneumoniae Isolates in Puerto Rico
The image on cover of the PRHSJ was generated and edited using artificial intelligence (AI) -Grok, Gemini, and Copilot- to conceptually illustrate a topic discussed in one of the publications about Microbiome. This image does not represent a real subject.
PDF

Keywords

Invasive Pneumococcal Disease
Non-invasive Pneumococcal Disease
Streptococcus pneumoniae
S. pneumoniae
Puerto Rico

How to Cite

García-Rivera, E. J., Sánchez, M. del C., Miranda, E. I., González, M., Torres, H., Torres, P., … Ron, Y. (2026). Serotype Distribution among Streptococcus pneumoniae Isolates in Puerto Rico. Puerto Rico Health Sciences Journal, 45(1), 16–22. Retrieved from https://prhsj.rcm.upr.edu/index.php/prhsj/article/view/3664

Abstract

Objective: S. pneumoniae infections remain a significant cause of morbidity and mortality despite vaccine availability. Limited information exists about current pneumococcal serotypes transmission in Puerto Rico. Our study aimed to describe the serotype distribution of S. pneumoniae isolates in Puerto Rico and its patients’ demographic characteristics. Methods: This prospective laboratory-based observational study from 25 hospitals in Puerto Rico (April 2021-July 2023) collected specimens positive for S. pneumoniae and serotyped them using the Pneumotest-Latex assay and the Quellung reaction tests. A summary of the distribution of S. pneumoniae isolates is presented. Results: Nineteen specimens were received from sterile (8/19, 42.1%), and non-sterile sites (11/19,
57.9%). All sterile specimens were isolated from blood samples. Most specimens came from male patients (16/19, 84.2%), the median age was 67 years (range: 8 months to 87 years) and came from different geographic regions. Thirteen serotypes were identified: 3 ( two patients), 6A (two patients), 11C, 11D, 15A, 15C, 19A (two patients), 19B, 19C (two patients ), 19F (two patients ), 22A, 34 (two patients ), and 35. Of these, nine (69.2%) were not covered in PPSV23 and PCV13 (available vaccines being used prior and by the time of specimen collection period), three (23%) were covered by both PPSV23, and PCV13, and one (8%) by PCV13 only. Conclusion: Our findings highlight the importance of continuous surveillance to detect early serotype changes, ongoing vaccination to avoid preventable infections and complications, and pursuing new higher-valency vaccines with broad serotype coverage to address the evolving pneumococcal disease epidemiology.

PDF
Authors who publish with this journal agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).